11/07/2025 16:00
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Takeda (TSE:4502/NYSE:TAK) today announced new interim data from the Phase 1b, open-label, proof-of-concept study of subcutaneous mezagitamab (TAK-079), an anti-CD38 monoclonal antibody with disease-modifying potential, in primary immunoglobulin A (IgA) nephropathy. Data from the study showed that kidney function (eGFR) remained stable in patients with IgA nephropathy through Week 96 – up to 18 months after the last mezagitamab dose.1 The results were presented at the American Society of Nephro...
AFP photographer Christina Assi carries the Olympic Flame in honour of journalists killed on duty
AFP photographer Christina Assi, who was severely injured on assignment last October in Lebanon, will carry the Olympic Flame on Sunday, 21 July, in Vincennes, France, "to pay tribute to those who have fallen" while doing their job as journalists, she explained.
Christina Assi, 29, was struck by a tank shell on October 13, 2023 while reporting on cross-border clashes between the Israeli army and armed groups in southern Lebanon, alongside six other colleagues.
Anglais